GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » Cash Flow from Investing

REVB (Revelation Biosciences) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2025, Revelation Biosciences spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Revelation Biosciences gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2025.


Revelation Biosciences Cash Flow from Investing Historical Data

The historical data trend for Revelation Biosciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Cash Flow from Investing Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
- -0.13 - - -0.02

Revelation Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 - -0.02 0.02 -

Revelation Biosciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Revelation Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Revelation Biosciences's Cash Flow from Investing for the quarter that ended in Mar. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (NAS:REVB) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Revelation Biosciences's purchase of property, plant, equipment for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Revelation Biosciences's sale of property, plant, equipment for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Revelation Biosciences's purchase of business for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Revelation Biosciences's sale of business for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Revelation Biosciences's purchase of investment for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Revelation Biosciences's sale of investment for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Revelation Biosciences's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Revelation Biosciences's cash from discontinued investing activities for the three months ended in Mar. 2025 was 0.00 Mil. It means Revelation Biosciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Revelation Biosciences's cash from other investing activities for the three months ended in Mar. 2025 was $0.00 Mil. It means Revelation Biosciences paid $0.00 Mil for other investing activities.


Revelation Biosciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences Business Description

Traded in Other Exchanges
N/A
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Executives
George F Tidmarsh director, 10 percent owner
Lakhmir S Chawla director 1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l other: Former 10% owner 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif other: Former 10% Owner 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a. other: Former 10% owner 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris other: Former 10% owner 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd other: Former 10% owner 22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa other: Former 10% owner 25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke director, officer: Chief Executive Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver director 725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii officer: Chief Financial Officer 3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis 10 percent owner 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc 10 percent owner 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606